Clinical Trial Update: Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of XL147 (SAR245408) in advanced or recurrent endometrial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Neoplasms

Drugs mentioned

• XL147 (SAR245408)

Snippet

Sponsor: Sanofi | Conditions: Endometrial Cancer, Endometrial Neoplasms | Phase 2 | Status: COMPLETED